Xencor (XNCR) Stock Forecast & Price Target

Xencor is viewed favorably because its XmAb platform has already produced validated drug candidates and continues to generate multiple near-term catalysts across oncology and immunology, reducing dependence on any single asset. XmAb819 stands out as the key re-rating driver, with ESMO data expected to clarify response rate, durability, dosing, and safety; maintenance of about 25% ORR, >6-month mPFS, and mostly grade 1/2 CRS would support phase III advancement and help justify an estimated ~$800M peak revenue opportunity in late-line ccRCC. The company also looks financially resilient, with 2Q26 EPS of $(0.29), YE26 cash guidance of $420–440MM, and runway through 2028, while royalties and milestones support continued development of XmAb942, XmAb541, XmAb808, and other pipeline assets.

Xencor is viewed negatively because its value remains heavily dependent on uncertain clinical readouts, with the key ccRCC program needing sustained ORR in a larger dataset and only modest PFS to de-risk a 2027 registrational study. The downside case is severe if target-dose activity fades, as the company could face a 50% stock decline in the worst scenario and continued uncertainty around RP3D selection, while even the mixed case implies limited differentiation and only partial path preservation. Fundamentally, the company also faces financing pressure before commercialization of its wholly owned portfolio, plus clinical, regulatory, competitive, and partnership risks, making collaboration and licensing revenue an insufficient cushion against program setbacks.